Zydus Lifesciences Ltd - 532321 - Corporate Action-Buy back
Buyback of shares09-02-2024
Zydus Lifesciences Ltd - 532321 - Board Meeting Outcome for Buyback Of Shares
Buyback of shares09-02-2024
Zydus Lifesciences Ltd - 532321 - Unaudited Financial Results For The Quarter And Nine Months Ended On December 31, 2023
Unaudited financial results for the quarter and nine months ended on December 31, 202309-02-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives Final Approvals from the USFDA for Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg and Dexamethasone Tablets USP, 2 mg.08-02-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Conference07-02-2024
Zydus Lifesciences Ltd - 532321 - Update on board meeting
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2024 ,inter alia, to consider and approve Update on board meeting-Proposal for buyback of shares05-02-2024
Zydus Lifesciences Ltd - 532321 - Demand Notice From CGST Jabalpur
Demand notice from CGST Jabalpur30-01-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q3 FY24 Post results Earnings Call details30-01-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Lifesciences launches Rexigo, the oral once-a-day pill for advanced prostate cancer patients in India.30-01-2024
Zydus Lifesciences Ltd - 532321 - Board Meeting Intimation for Quarterly Results
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2024 ,inter alia, to consider and approve Unaudited Financial Results for the quarter / nine months ended on December 31, 2023.29-01-2024